A5072612033- Vasculitis and related conditions
- Renal Diseases and Glomerulopathies
- Systemic Lupus Erythematosus Research
- Eosinophilic Disorders and Syndromes
- Urticaria and Related Conditions
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Sarcoidosis and Beryllium Toxicity Research
- Monoclonal and Polyclonal Antibodies Research
- Otitis Media and Relapsing Polychondritis
- Systemic Sclerosis and Related Diseases
- Liver Diseases and Immunity
- Autoimmune Bullous Skin Diseases
- Cell Adhesion Molecules Research
- Eosinophilic Esophagitis
- T-cell and B-cell Immunology
- Amyloidosis: Diagnosis, Treatment, Outcomes
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Complement system in diseases
- Inflammasome and immune disorders
- Platelet Disorders and Treatments
- Diabetes and associated disorders
- Chronic Lymphocytic Leukemia Research
- SARS-CoV-2 and COVID-19 Research
- Liver Disease Diagnosis and Treatment
- Atherosclerosis and Cardiovascular Diseases
IRCCS Humanitas Research Hospital
2023-2025
Istituti di Ricovero e Cura a Carattere Scientifico
2021-2025
University of Milano-Bicocca
2016-2024
Azienda Ospedaliera San Gerardo
2018-2024
University of Milan
1986-2024
Humanitas University
2023
Applied Scientific Research (United States)
2023
Pediatric Nephrology of Alabama
2000-2022
ASST Melegnano e della Martesana
2022
Azienda Socio Sanitaria Territoriale Lariana
2021
Systemic vasculitis associated with autoantibodies to neutrophil cytoplasmic antigens (ANCA) is the most frequent cause of rapidly progressive glomerulonephritis. Renal failure at presentation carries an increased risk for ESRD and death despite immunosuppressive therapy. This study investigated whether addition plasma exchange was more effective than intravenous methylprednisolone in achievement renal recovery those who presented a serum creatinine >500 micromol/L (5.8 mg/dl). A total 137...
Abstract Objective Glomerulonephritis is a severe manifestation of systemic lupus erythematosus (SLE) that usually treated with an extended course intravenous (IV) cyclophosphamide (CYC). Given the side effects this regimen, we evaluated efficacy and toxicity low‐dose IV CYC prescribed as remission‐inducing treatment, followed by azathioprine (AZA) remission‐maintaining treatment. Methods In multicenter, prospective clinical trial (the Euro‐Lupus Nephritis Trial [ELNT]), randomly assigned 90...
Abstract Objective Churg‐Strauss syndrome (CSS) is classified among the so‐called antineutrophil cytoplasmic antibody–associated systemic vasculitides (AASVs) because of its clinicopathologic features that overlap with other AASVs. However, while antibodies (ANCAs) are consistently found in 75–95% patients Wegener's granulomatosis or microscopic polyangiitis, their prevalence CSS varies widely and clinical significance remains uncertain. We undertook this study to examine antigen specificity...
Anti-nuclear antibodies (ANA) are fundamental for the diagnosis of autoimmune diseases, and have been determined by indirect immunofluorescence assay (IIFA) decades. As demand ANA testing increased, alternative techniques were developed challenging classic IIFA. These platforms differ in their antigen profiles, sensitivity specificity, raising uncertainties regarding standardisation interpretation incongruent results. Therefore, an international group experts has created recommendations...
Objective: To update the follow-up of Euro-Lupus Nephritis Trial (ELNT), a randomised prospective trial comparing low-dose (LD) and high-dose (HD) intravenous (IV) cyclophosphamide (CY) followed by azathioprine (AZA) as treatment for proliferative lupus nephritis. Patients methods: Data survival kidney function were prospectively collected during 10-year period 90 patients in ELNT, except 6 lost to follow-up. Results: Death, sustained doubling serum creatinine end-stage renal disease rates...
Eosinophilic granulomatosis with polyangiitisObjective: To develop disease-specific recommendations for the diagnosis and management of eosinophilic polyangiitis (Churg-Strauss syndrome) (EGPA).Methods: The EGPA Consensus Task Force experts comprised 8 pulmonologists, 6 internists, 4 rheumatologists, 3 nephrologists, 1 pathologist allergist from 5 European countries USA.Using a modified Delphi process, list 40 questions was elaborated by 2 members sent to all participants prior...
Abstract Objective In the Euro‐Lupus Nephritis Trial (ELNT), 90 patients with lupus nephritis were randomly assigned to a high‐dose intravenous cyclophosphamide (IV CYC) regimen (6 monthly pulses and 2 quarterly escalating doses) or low‐dose IV CYC of 500 mg given at intervals weeks), each which was followed by azathioprine (AZA). After median followup 41 months, difference in efficacy between regimens not observed. The present analysis undertaken extend identify prognostic factors. Methods...
Abstract Eosinophilic granulomatosis with polyangiitis (EGPA) is a rare inflammatory disease of unknown cause. 30% patients have anti-neutrophil cytoplasmic antibodies (ANCA) specific for myeloperoxidase (MPO). Here, we describe genome-wide association study in 676 EGPA cases and 6809 controls, that identifies 4 EGPA-associated loci through conventional case-control analysis, additional associations conditional false discovery rate approach. Many variants are also associated asthma six...
Mepolizumab proved to be an efficacious treatment for eosinophilic granulomatosis with polyangiitis (EGPA) at a dose of 300 mg every 4 weeks in the randomized, controlled MIRRA trial. In few recently reported studies, successful real-life experiences approved treating severe asthma (100 weeks) were observed. We undertook this study assess effectiveness and safety mepolizumab 100 large European EGPA cohort.We included all patients treated recruiting centers 2015-2020. Treatment response was...
Despite newer treatments with immunosuppressive agents, there still exists a considerable morbidity and mortality risk among patients anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV). Since 1994 the European Vasculitis Society (EUVAS) has aimed for an improved outcome AAV, conducting several prospective randomized controlled trials (RCTs). The aim present study was to further evaluate long-term survival of AAV included in seven RCTs conducted by EUVAS as well identify...
T-helper type 2 responses are crucial in Churg-Strauss syndrome (CSS) and may enhance the production of IgG4 antibodies. The authors assessed immune response CSS patients.The included 46 consecutive patients with (24 active 22 quiescent disease), 26 granulomatosis polyangiitis (GPA, Wegener's), 25 atopic asthma 20 healthy controls determined serum IgG, IgM, IgA, IgE IgG subclass levels. Tissue infiltration by plasma cells was nine CSS, 10 GPA, chronic sinusitis (11 11 without...
Abstract Objective To explore the association between HLA alleles and Churg‐Strauss syndrome (CSS), to investigate potential influence of on clinical spectrum disease. Methods Low‐resolution genotyping HLA–A, HLA–B, HLA–DR loci TNFA −238A/G −308A/G single‐nucleotide polymorphisms were performed in 48 consecutive CSS patients 350 healthy controls. Results The frequency HLA–DRB1*07 allele was higher than controls (27.1% versus 13.3%; χ 2 = 12.64, P 0.0003, corrected [ corr ] 0.0042, odds ratio...
Objectives To evaluate changes in demographic, clinical and histological presentation, prognosis of lupus nephritis (LN) over time. Patients methods We studied a multicentre cohort 499 patients diagnosed with LN from 1970 to 2016. The 46-year follow-up was subdivided into three periods (P): P1 1970–1985, P2 1986–2001 P3 2002–2016, accordingly grouped based on the year diagnosis. Predictors patient renal survival were investigated by univariate multivariate proportional hazards Cox regression...
The respiratory manifestations of eosinophilic granulomatosis with polyangiitis (EGPA) have not been studied in detail. In this retrospective multicentre study, EGPA was defined by asthma, eosinophilia and at least one new onset extra-bronchopulmonary organ manifestation disease. study population included 157 patients (mean± sd age 49.4±14.1 years), a mean± blood eosinophil count 7.4±6.4×10 9 L −1 diagnosis. There 11.8±18.2 years from the asthma to diagnosis EGPA, 1.4±8.4 first peripheral...
Summary Background and objectives The discovery of different podocyte autoantibodies in membranous nephropathy (MN) raises questions about their pathogenetic clinical meaning. This study sought to define antibody isotypes correlations; compare levels MN, other glomerulonephritides, controls; determine association with outcomes. Design, setting, participants, & measurements Serum IgG 1 , 3 4 against aldose reductase (AR), SOD2, α-enolase (αENO) were measured at diagnosis 186 consecutive...